Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Current Deferred Revenue: 2023-2025

Historic Current Deferred Revenue for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Sep 2025 value amounting to $2.7 million.

  • Tonix Pharmaceuticals Holding's Current Deferred Revenue was N/A to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2024, which is 39.06% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Current Deferred Revenue of $2.7 million as of Q3 2025, which was down 11.21% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Current Deferred Revenue registered a high of $3.0 million during Q2 2025, and its lowest value of $1.8 million during Q4 2024.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Current Deferred Revenue had a median value of $2.7 million in 2025 and averaged $2.5 million.
  • Data for Tonix Pharmaceuticals Holding's Current Deferred Revenue shows a maximum YoY slumped of 39.06% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Current Deferred Revenue stood at $3.0 million in 2023, then slumped by 39.06% to $1.8 million in 2024, then reached $2.7 million in 2025.
  • Its Current Deferred Revenue stands at $2.7 million for Q3 2025, versus $3.0 million for Q2 2025 and $1.9 million for Q1 2025.